Regulation of Cell and Gene Therapy Medicinal Products in Taiwan

被引：1

作者：

Lin, Yi-Chu ^{[1
]}

Wang, Po-Yu ^{[1
]}

Tsai, Shih-Chih ^{[1
]}

Lin, Chien-Liang ^{[1
]}

Tai, Hsuen-Yung ^{[1
]}

Lo, Chi-Fang ^{[2
]}

Wu, Shiow-Ing ^{[2
]}

Chiang, Yu-Mei ^{[2
]}

Liu, Li-Ling ^{[1
]}

机构：

[1] Taiwan Food & Drug Adm, Div Med Prod, Taipei 11561, Taiwan

[2] Taiwan Food & Drug Adm, Taipei 11561, Taiwan

来源：

REGULATORY ASPECTS OF GENE THERAPY AND CELL THERAPY PRODUCTS: A GLOBAL PERSPECTIVE | 2015年 / 871卷

关键词：

Taiwan Food and Drug Administration (TFDA); Cell therapy medicinal products; Gene therapy medicinal products; Clinical trials; Investigational New Drug (IND); New Drug Application (NDA); Medical practice; New medical practice; Medicinal products; TFDA Guidance; Points to consider;

D O I：

10.1007/978-3-319-18618-4_10

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Owing to the rapid and mature development of emerging biotechnology in the fields of cell culture, cell preservation, and recombinant DNA technology, more and more cell or gene medicinal therapy products have been approved for marketing, to treat serious diseases which have been challenging to treat with current medical practice or medicine. This chapter will briefly introduce the Taiwan Food and Drug Administration (TFDA) and elaborate regulation of cell and gene therapy medicinal products in Taiwan, including regulatory history evolution, current regulatory framework, application and review procedures, and relevant jurisdictional issues. Under the promise of quality, safety, and efficacy of medicinal products, it is expected the regulation and environment will be more flexible, streamlining the process of the marketing approval of new emerging cell or gene therapy medicinal products and providing diverse treatment options for physicians and patients.

引用

页码：181 / 194

页数：14